Global Schizophrenia Drug Market Overview
Schizophrenia is a chronic and severe mental disorder which affects the person’s health, thinking, feeling and behavior. Symptoms of schizophrenia can be delusions, hallucinations, disorganized thinking (speech), extremely disorganized or abnormal motor behavior. People with schizophrenia require lifelong treatment.If the medications are not provided on time may lead to serious medical complications.
Schizophrenia is diagnosed 1.4 times more frequently in males than in females, as the onset is earlier in men. The peak age of onset is 20-28 for males and 25-32 for females. The rising burden of the disease and the increasing need to manage it effectively is driving the growth of the market study, although schizophrenia is not as common as other mental disorders. The medications often provided by the doctors for schizophrenia is called antipsychotics. They ease symptoms such as delusions and hallucinations. Antipsychotics drugs works on chemicals such as dopamine and serotonin which stabilizes the mental functioning of the body.
Impact of COVID-19 on Global Schizophrenia market
According to the Centre for Disease Control and Prevention report in year 2020, more than 2 in 5 U.S. residents report struggling with mental or behavioral health issues associated with coronavirus disease (Covid-19) pandemic, including anxiety, depression, and increased substance use and suicidal thoughts. Further, the report published in the August 2020 of the Morbidity and Mortality Weekly Report, also notes that certain groups are disproportionately affected by COVID–related stresses, including adults and younger, Hispanic and black individuals, essential workers, unpaid caregivers for adults, and those receiving treatment for preexisting psychiatric conditions. The above mentioned facors are expected to drive the schizophrenia drug market.
Global Schizophrenia Drug Market Dynamics
Rising Cases of Schizophrenia
The primary factors driving the growth of the global schizophrenia drug market are rising cases of schizophrenia. Increasing research and development in schizophrenia treatment of geriatric individuals is rising. According to the National Institute of Mental Health (NIHM). Schizophrenia is one of the top leading 15 causes of disability world worldwide.
According to the World Health Organization in 2017, 20 million of the people are affected by schizophrenia worldwide. People with schizophrenia are 2 – 3 times more likely to die early as compared to the general population.
Rising initiatives by government bodies
Growing burden of schizophrenia and associated disorders is causing the drug market shares to increase rapidly. Focus of government organizations and health organizations towards schizophrenia drug market is also increasing steadily. There is increased investment in research and development.. Increasing number of patients seeking treatment and increasing demand for improved healthcare infrastructure are expected to drive the market.
Drug Addiction and Patent expiry
Patent expiry of major drugs is another restraint of schizophrenia market. Asenapine is a kind of drug which is used to treat schizophrenia and bipolar disorder. Saphris, is an expensive drug with no generic alternative, with patent expiry in 2020, meaning a more affordable mental health treatment may be available, which may hamper the market value of the market.
Global Schizophrenia Drug Market Segmentation
Source: Prophecy Market Insights |Disclaimer: Data is only a representation. Actual data may vary in the final report.
The global schizophrenia drug market is segmented based on type, therapeutic class, treatment, and by region.
On the basis of type, the global schizophrenia drug market is segmented into Paranoid Schizophrenia, Hebephrenic Schizophrenia, Catatonic Schizophrenia and Undifferentiated Schizophrenia. Based on therapeutics class, the drug market is segmented into Second Generation Antipsychotics, Third Generation and other therapeutics class.
Moreover, the Second generation antipsychotics is sub-segmented into Risperdal (Risperidone), Invega (Paliperidone), Zyprexa (Olanzapine), Geodon (Ziprasidone), Seroquel (Quetiapine), Latuda (Lurasidone).
On basis of treatment, the schizophrenia drug market is segmented into oral and injectable. The drug segment is expected to decrease from 2022 due to patent expiry. Further, failure in clinical trials is also expected to hamper the growth of schizophrenia drug market.
Regional Insights:
Regionally, the global schizophrenia drug market was dominated by the North America. According to the study by the Centre of Disease Control and Prevention in January 2018, 1 in 25 of Americans suffered from serious mental health problems, such as depression, schizophrenia and bipolar disorder, which supports the growth of schizophrenia drug market. Presence of key players along with awareness within the citizens of North America supports the growth of market.
Asia pacific is expected to grow at significant CAGR due to increasing initiatives of government and rising prevalence of schizophrenia.
Report Scope:
|
Attribute |
Details |
|
Base year for estimation |
2020 |
|
Forecast period |
2020 – 2029 |
|
Market representation |
Revenue in USD Million & CAGR from 2020 – 2029 |
|
Market Segmentation |
By Type - Paranoid Schizophrenia, Hebephrenic Schizophrenia, Catatonic Schizophrenia and Undifferentiated Schizophrenia By Treatment - Oral and Injectable By Therapeutic Class - Second Generation Antipsychotics, (Risperdal (Risperidone), Invega (Paliperidone), Zyprexa (Olanzapine), Geodon (Ziprasidone), Seroquel (Quetiapine), Latuda (Lurasidone)) Third Generation Antipsychotics and Other Therapeutic Classes By Region - North America, Europe, Asia Pacific, Latin America and Middle East & Africa |
|
Regional scope |
North America - U.S., Canada Europe - UK, Germany, Spain, France, Italy, Russia, Rest of Europe Asia Pacific - Japan, India, China, South Korea, Australia, Rest of Asia-Pacific Latin America - Brazil, Mexico, Argentina, Rest of Latin America Middle East & Africa - South Africa, Saudi Arabia, UAE, Rest of Middle East & Africa |
|
Report coverage |
Revenue forecast, company share, competitive landscape, growth factors, and trends |
Segments Covered in the Report:
This report forecasts revenue growth at global, regional, and country levels and provides an analysis of the latest industry trends and opportunities in each of the sub-segments from 2019 to 2029. For the purpose of this study, has segmented the global schizophrenia drug market report based on type, therapeutics class, by treatment , second generation antipsychotics, third generation antipsychotics and by region.
Global Schizophrenia Drug Market, By Region:
-
-
- North America
-
- U.S.
- Canada
-
- Europe
-
- Germany
- UK
- France
- Russia
- Italy
- Rest of Europe
-
- Asia Pacific
-
- China
- India
- Japan
- South Korea
- Rest of Asia Pacific
-
- Latin America
-
- Brazil
- Mexico
- Rest of Latin America
-
- Middle East & Africa
-
- GCC
- Israel
- South Africa
- Rest of Middle East & Africa
-
- North America
-
Global Schizophrenia Drug Market Key Players
The key players operating in the global schizophrenia drug market include Johnson & Johnson, Bristol-Myers Squibb and Company/Otsuka Pharmaceuticals, AstraZeneca, Eli Lilly, Alkermes, Sumitomo Dainippon Pharma, Pfizer, Vanda Pharmaceuticals, and Allergan/Geodon Ritcher. The key players are involved in partnership or merger for research and development of schizophrenia drug market. For instance, in 2019, Gedeon Richter Plc along with Allergen announced the amendment of its existing license agreement for cariprazine to include major markets in Latin America (Argentina, Brazil, Chile, Colombia, Ecuador, Mexico, Peru and Venezuela). This is expected to increase the sale of schizophrenia drug globally.
Global Schizophrenia Drug Market Company Profile
- Johnson & Johnson*
- Company Overview
- Product Portfolio
- Key Highlights
- Financial Overview
- Business Strategies
- Bristol-Myers Squibb/Otsuka Pharmaceuticals
- AstraZeneca
- Eli Lilly
- Alkermes
- Sumitomo Dainippon Pharma
- Pfizer
- Vanda Pharmaceuticals
- Allergan/Geodon Ritcher
Global Schizophrenia Drug Market Table of Contents
- Research Objective and Assumption
- Preface
- Research Objectives
- Study Scope
- Years Considered for the study
- Assumptions
- Abbreviations
- Research Methodology
- Research data
- Primary Data
- Primary Interviews
- Primary Breakdown
- Key data from Primary Sources
- Key Thickness Insights
- Secondary Data
- Major Secondary Sources
- Secondary Sources
- Market Estimation
- Top-Down Approach
- Approach for estimating Market Share by Top-Down Analysis (Supply Side)
- Bottom-Up Approach
- Approach for estimating market share by Bottom-up Analysis (Demand Side)
- Market Breakdown and Data Triangulation
- Research Assumptions
- Market Purview
- Executive Summary
- Key Findings—Global Outlook for Schizophrenia Drug Strategies
- Key Questions this Study will Answer
- Market Snippet, By Type
- Market Snippet, By Treatment
- Market Snippet, By Therapeutic Class
- Market Snippet, By Region
- Opportunity Map Analysis
- Executive Summary—3 Big Predictions
- Market Dynamics, Regulations, and Trends Analysis
- Market Dynamics
- Drivers
- Restraints
- Market Opportunities
- Market Trends
- DR Impact Analysis
- PEST Analysis
- Porter’s Five Forces Analysis
- Opportunity Orbit
- Market Investment Feasibility Index
- Macroeconomic Factor Analysis
- Market Dynamics
- Global Schizophrenia Drug Market, By Type, 2020 – 2029, (US$ Mn)
- Overview
- Market Value and Forecast (US$ Mn), and Share Analysis (%), 2020 – 2029
- Y-o-Y Growth Analysis (%), 2020 – 2029
- Segment Trends
- Paranoid Schizophrenia
- Overview
- Market Size and Forecast (US$ Mn), and Y-o-Y Growth (%), 2020 – 2029
- Hebephrenic Schizophrenia
- Overview
- Market Size and Forecast (US$ Mn), and Y-o-Y Growth (%), 2020 – 2029
- Catatonic Schizophrenia
- Overview
- Market Size and Forecast (US$ Mn), and Y-o-Y Growth (%), 2020 – 2029
- Undifferentiated Schizophrenia
- Overview
- Market Size and Forecast (US$ Mn), and Y-o-Y Growth (%), 2020 – 2029
- Overview
- Global Schizophrenia Drug Market, By Treatment, 2020 – 2029, (US$ Mn)
- Overview
- Market Value and Forecast (US$ Mn), and Share Analysis (%), 2020 – 2029
- Y-o-Y Growth Analysis (%), 2020 – 2029
- Segment Trends
- Oral
- Overview
- Market Size and Forecast (US$ Mn), and Y-o-Y Growth (%), 2020 – 2029
- Injectable
- Overview
- Market Size and Forecast (US$ Mn), and Y-o-Y Growth (%), 2020 – 2029
- Overview
- Global Schizophrenia Drug Market, By Therapeutic Class, 2020 – 2029, (US$ Mn)
- Overview
- Market Value and Forecast (US$ Mn), and Share Analysis (%), 2020 – 2029
- Y-o-Y Growth Analysis (%), 2020 – 2029
- Segment Trends
- Second Generation Antipsychotics
- Overview
- Market Size and Forecast (US$ Mn), and Y-o-Y Growth (%), 2020 – 2029
- Risperdal (Risperidone)
- Overview
- Market Size and Forecast (US$ Mn), and Y-o-Y Growth (%), 2020 – 2029
- Invega (Paliperidone)
- Overview
- Market Size and Forecast (US$ Mn), and Y-o-Y Growth (%), 2020 – 2029
- Zyprexa (Olanzapine)
- Overview
- Market Size and Forecast (US$ Mn), and Y-o-Y Growth (%), 2020 – 2029
- Geodon (Ziprasidone)
- Overview
- Market Size and Forecast (US$ Mn), and Y-o-Y Growth (%), 2020 – 2029
- Seroquel (Quetiapine)
- Overview
- Market Size and Forecast (US$ Mn), and Y-o-Y Growth (%), 2020 – 2029
- Latuda (Lurasidone)
- Overview
- Market Size and Forecast (US$ Mn), and Y-o-Y Growth (%), 2020 – 2029
- Third Generation Antipsychotics
- Overview
- Market Size and Forecast (US$ Mn), and Y-o-Y Growth (%), 2020 – 2029
- Others
- Overview
- Market Size and Forecast (US$ Mn), and Y-o-Y Growth (%), 2020 – 2029
- Overview
- Global Schizophrenia Drug Market, By Region, 2020 – 2029, (US$ Mn)
- Overview
- Market Value and Forecast (US$ Mn), and Share Analysis (%), 2020 – 2029
- Y-o-Y Growth Analysis (%), 2020 – 2029
- Regional Trends
- North America
- Market Size and Forecast (US$ Mn), By Type, 2020 – 2029
- Market Size and Forecast (US$ Mn), By Treatment, 2020 – 2029
- Market Size and Forecast (US$ Mn), By Therapeutic Class, 2020 – 2029
- Market Size and Forecast (US$ Mn), By Country, 2020 – 2029
- U.S.
- Canada
- Europe
- Market Size and Forecast (US$ Mn), By Type, 2020 – 2029
- Market Size and Forecast (US$ Mn), By Treatment, 2020 – 2029
- Market Size and Forecast (US$ Mn), By Therapeutic Class, 2020 – 2029
- Market Size and Forecast (US$ Mn), By Country, 2020 – 2029
- Germany
- UK
- France
- Russia
- Italy
- Rest of Europe
- Asia Pacific
- Market Size and Forecast (US$ Mn), By Type, 2020 – 2029
- Market Size and Forecast (US$ Mn), By Treatment, 2020 – 2029
- Market Size and Forecast (US$ Mn), By Therapeutic Class, 2020 – 2029
- Market Size and Forecast (US$ Mn), By Country, 2020 – 2029
- China
- India
- Japan
- South Korea
- Rest of Asia Pacific
- Latin America
- Market Size and Forecast (US$ Mn), By Type, 2020 – 2029
- Market Size and Forecast (US$ Mn), By Treatment, 2020 – 2029
- Market Size and Forecast (US$ Mn), By Therapeutic Class, 2020 – 2029
- Market Size and Forecast (US$ Mn), By Country, 2020 – 2029
- Brazil
- Mexico
- Rest of Latin America
- Middle East & Africa
- Market Size and Forecast (US$ Mn), By Type, 2020 – 2029
- Market Size and Forecast (US$ Mn), By Treatment, 2020 – 2029
- Market Size and Forecast (US$ Mn), By Therapeutic Class, 2020 – 2029
- Market Size and Forecast (US$ Mn), By Country, 2020 – 2029
- GCC
- Israel
- South Africa
- Rest of Middle East
- Overview
- Competitive Landscape
- Heat Map Analysis
- Market Presence and Specificity Analysis
- Company Profiles
-
- Johnson & Johnson.
- Company Overview
- Product Portfolio
- Key Highlights
- Financial Overview
- Business Strategies
- Johnson & Johnson.
-
- Bristol-Myers Squibb/Otsuka Pharmaceuticals
- AstraZeneca
- Eli Lilly
- Alkermes
- Sumitomo Dainippon Pharma
- Pfizer
- Vanda Pharmaceuticals
- Allergan/Geodon Ritcher
- The Last Word
- Future Impact
- About Us
- Contact
FAQs
The global schizophrenia drug market is segmented based on the type, therapeutics class, by treatment, second generation antipsychotics, and third generation’s antipsychotics and by region
Rising initiatives by government bodies due to the schizophrenia drug market is the major factor driving growth of the global market
The global schizophrenia drug market was dominated by the U.S. with more than 50.0% share in 2016. The schizophrenia market is largely generic accounting for almost 65.0% of prescription volume.
Companies are continuously rising the production and supply of drugs and antipsychotics in the market.Drug market for schizophrenia is increasing day by day.